MUMBAI: Global pharma companies have now increased the amount of outsourced clinical research — a critical part of new drug development — to emerging economies, and clinical trials done in India have grown massively. A large pool of naive patients (that have not been exposed to too many medicines), a larger spectrum of disease profiles and a genetically distinct group are proving to be trump cards for India. According to a publication by the US National Institute of Health, the number of clinical trials conducted in India has more than doubled in just over a year.
